Programs

  • Program 1 [2020]

    MTF PROVIDES ALLOGRAFT TISSUES TO THE MEDICAL COMMUNITY. SINCE ITS INCEPTION IN 1987, MTF, THE NATION'S LEADING TISSUE BANK, HAS RECEIVED TISSUE DONATIONS FROM OVER 150,000 DONORS. IN 2020, MTF RECOVERED TISSUE FROM OVER 5,500 DONORS FOR USE IN MUSCULOSKELETAL AND BONE ALLOGRAFT APPLICATIONS, OVER 6,300 DONORS FOR USE IN BURN, GENERAL, AND PLASTIC SURGERY APPLICATIONS, OVER 1,100 BIRTH TISSUE DONORS FOR USE PREDOMINANTLY IN WOUND CARE APPLICATIONS AND OVER 683 DONORS FOR ORGANS AND TISSUES FOR RESEARCH. OVERALL, MTF DISTRIBUTED APPROXIMATELY 400,000 UNITS OF ALLOGRAFT TISSUE DURING 2020. IN ADDITION TO THE FURTHERANCE OF THE MISSION DRIVEN RESULTS IN 2019 (HIGHLIGHTED BELOW) AND GIVEN THE CHALLENGES FACED IN 2020, MTF CONTINUES TO DEVELOP INNOVATIVE TISSUE FORMS, FOCUSED ON SOLVING REAL-WORLD, CLINICAL PROBLEMS. MTF HAS ALSO CONTINUED ITS EFFORTS TO PROVIDE SPECIAL RESEARCH TISSUE FOR RESEARCH PERFORMED BY MEMBERS OF THE ARMED FORCES INSTITUTE OF REGENERATIVE MEDICINE, AN ORGANIZATION DEDICATED TO DEVELOPING MEDICAL THERAPIES FOR WOUNDED SOLDIERS. MTF CONTINUED TO MAKE TISSUE FORMS AVAILABLE IN THE ORTHOPEDIC, PLASTIC AND RECONSTRUCTIVE SURGERY, AND WOUND CARE MARKETS. IN THE ORTHOPEDICS FRANCHISE, MTF DEVELOPED NEW PARTNERSHIPS, FURTHER ENHANCING ITS OUTREACH, DISTRIBUTION NETWORK, AND ABILITY TO BRING DONATED ALLOGRAFT TISSUES TO PATIENT RECIPIENTS. IN THE PLASTIC AND RECONSTRUCTIVE SURGERY FRANCHISE, MTF DEVELOPED STRATEGIC INTER-INDUSTRY PARTNERSHIPS TO UTILIZE CROSS- ORGANIZATIONAL EXPERTISE, GREATLY EXPANDING DONATION NETWORKS AND INCREASING PROCESSING CAPACITY, AND THEREFORE THE AVAILABILITY OF HUMAN DERMAL AND SPLIT-THICKNESS ALLOGRAFTS. MTF'S WOUND CARE DIVISION WAS ABLE TO EXPAND THE DISTRIBUTION OF ITS WOUND CARE PORTFOLIO TO MORE RECIPIENTS IN THE VA AND PUBLIC HOSPITALS IN 2020. MTF CONTINUED ITS CLINICAL STUDY PORTFOLIO, INCREASING ITS COMPENDIUM OF CLINICAL DATA FOR EXPANDED REIMBURSEMENT IN WOUND CARE AND PLASTIC AND RECONSTRUCTIVE SURGERY PROCEDURES. IN ADDITION TO RETAINING PERSONNEL AND CAREFULLY MONITORING AND ADAPTING TO SUPPLY CHAIN CHALLENGES, MTF WAS ALSO ABLE TO DONATE PERSONAL PROTECTIVE EQUIPMENT (PPE) TO LOCAL HEALTHCARE FACILITIES IN NEED DURING THE PANDEMIC. MTF CONTINUES INTO 2021 DEVELOPING NOVEL TISSUE FORMS AND PROCESSING METHODS TO SOLVE CLINICAL PROBLEMS. MTF IS FOCUSED ON HONORING THE DONATED GIFT OF HUMAN TISSUE, ENSURING QUALITY TISSUE FORMS, MAXIMIZING THE DONOR GIFT, AND WORKING WITH SURGEONS TO SAVE AND HEAL LIVES. ___________________________________________________________________________ IN 2019, MTF CONTINUED TO INCREASE TISSUE UTILIZATION AND PLACEMENT OF TISSUE FORMS IN THE ORTHOPEDIC, PLASTIC AND RECONSTRUCTIVE SURGERY, AND WOUND CARE MARKETS. IN THE ORTHOPEDICS MARKET, MTF LAUNCHED QUICKGRAFT, A PRE-SUTURED TENDON. THIS TECHNOLOGY ALLOWS MTF AND SURGEON PARTNERS TO HONOR THE DONATED GIFT BY INCREASING THE PREDICTABILITY OF SURGICAL PROCEDURES FOR THE PATIENT. MTF ALSO CONTINUED TO INCREASE ITS UTILITY OF THE MOPS OSTEOCHONDRAL PRESERVATION TECHNOLOGY. THIS TECHNOLOGY FURTHER HONORS THE GIFT BY EXTENDING THE STORAGE LIFE OF DONATED TISSUE. IN 2019 MTF BEGAN TO DISTRIBUTE CC+, A CORTICAL-CANCELLOUS BONE VOID FILLER. FURTHERMORE, MTF LAUNCHED A NEW CORTICAL FIBER BASED BONE VOID FILLER, FIBER FUSE, WHICH POSSESSES OSTEO-INDUCTIVE, OSTEO-CONDUCTIVE POTENTIAL AND EXCELLENT HANDLING PROPERTIES. IN PLASTIC AND RECONSTRUCTIVE SURGERY (PRS), MTF LAUNCHED FLEXHD PRE, AN INNOVATIVE TISSUE FORM, DESIGNED TO ALLOW SURGEONS GREATER OPTIONS FOR BREAST RECONSTRUCTION PROCEDURES FOLLOWING MASTECTOMY. THE MTF PRS DIVISION ALSO SAW AN INCREASED USE OF RENUVA, AN ADIPOSE MATRIX, FOR USES SUCH AS RECONSTRUCTION AND TREATMENT OF SMALL VOLUME DEFECTS WHERE HOST FAT HAS EITHER DECREASED OR BEEN DEGRADED OR LOST DUE TO TRAUMA OR DISEASE. MTF'S WOUND CARE DIVISION DEVELOPED AND LAUNCHED SOMAGEN, AN ACELLULAR DERMAL ALLOGRAFT AND LENEVA A SOFT TISSUE ADIPOSE MATRIX. MTF ALSO CONTINUED EXPANDING THE DISTRIBUTION OF ITS WOUND CARE PORTFOLIO TO MORE RECIPIENTS IN THE VA AND PUBLIC HOSPITALS THROUGHOUT THE YEAR. MTF CONTINUED TO EXPAND ITS CLINICAL STUDY PORTFOLIO, INCREASING ITS COMPENDIUM OF CLINICAL DATA FOR EXPANDED REIMBURSEMENT IN WOUND CARE AND BREAST RECONSTRUCTION. MTF CONTINUED ITS PROSPECTIVE RANDOMIZED CLINICAL TRIAL FOR FLEXHD PLIABLE ACELLULAR DERMAL MATRIX FOR USES SUCH AS BREAST RECONSTRUCTION FOLLOWING MASTECTOMY. IN THE WOUND CARE MARKET, CLINICAL STUDIES AND RESEARCH DATA HAVE PROVIDED THE INFORMATION FOR MTF TO ATTAIN COVERAGE FOR APPROXIMATELY 73% OF ALL COVERED AMERICAN LIVES IN 2019. MTF CONTINUED ITS SUPPORT OF THE AMERICAN SOCIETY OF PLASTIC SURGEONS (ASPS) AND THE PLASTIC SURGERY FOUNDATION (PSF) WHICH PROVIDES OPPORTUNITIES FOR SURGEONS TO PERFORM ALLOGRAFT BASED RESEARCH TO ADVANCE THE SCIENCE OF ALLOGRAFT USE IN PLASTIC/RECONSTRUCTIVE PROCEDURES. MTF ALSO REMAINS COMMITTED TO SUPPORTING BREAST RECONSTRUCTION AWARENESS (BRA) DAY EACH YEAR AND INCLUDES EDUCATION FOR BOTH PATIENTS AND SURGEONS ON THE OPTIONS AVAILABLE TODAY FOR WOMEN, HELPING TO ENSURE SURVIVORS' RIGHTS TO MAKE AN INFORMED DECISION. MTF ALSO CONTINUED ITS FINANCIAL PLEDGE OF (1M OVER FIVE YEARS) TO SUPPORT BIOLOGIC RESEARCH THROUGH THE PLASTIC SURGERY FOUNDATION (PSF). MTF'S MISSION IS TO SAVE AND HEAL LIVES BY HONORING THE DONATED GIFT, SERVING PATIENTS AND ADVANCING SCIENCE. FOR INDIVIDUAL STORIES ABOUT DONOR FAMILIES, PLEASE VISIT MTF BIOLOGICS WEBSITE AT HTTPS://WWW.MTFBIOLOGICS.ORG/WHO-WE-SERVE/DONORS- COMMUNITY/DONORS-FAMILIES. STORIES ABOUT RECIPIENTS ARE ALSO AVAILABLE ON THE WEBSITE AT HTTPS://WWW.MTFBIOLOGICS.ORG/WHO-WE-SERVE/DONORS- COMMUNITY/RECIPIENTS.
    Geographies
    Not indicated
    Dates
    Jan 1, 2020 – Dec 31, 2020
    Source
    990
    No causes provided
    No populations provided
    –
    $393.3M

  • MTF Tissue Donation and Research Program

    MTF IS A GLOBAL NONPROFIT ORGANIZATION FOCUSED ON SAVING AND HEALING LIVES, EXPANDING INNOVATION POTENTIAL, HONORING DONATED GIFTS AND SERVING PATIENTS. MTF CONTINUES TO PROVIDE RESEARCH TISSUE AND GRANT FUNDING FOR RESEARCH AND DEVELOPMENT PERFORMED BY ACADEMIC CENTERS AND PIONEERING ENTERPRISES. IN 2023 MTF CONTINUED TO PURSUE ITS MISSION, AND MADE TISSUE FORMS AVAILABLE IN THE ORTHOPEDIC, PLASTIC AND RECONSTRUCTIVE SURGERY, AND WOUND CARE MARKETS THROUGH BOTH INTERNAL AND EXTERNAL DISTRIBUTION RELATIONSHIPS. MTF ORTHOPEDICS FOSTERED NEW PARTNERSHIPS AND EXPANDED ITS REACH BY LAUNCHING MULTIPLE NEW TISSUE FORMS IN 2023. THESE INNOVATIONS POSITIONED THE FOUNDATION AND OUR PARTNERS TO HELP MORE PATIENTS, WHILE FURTHER MAXIMIZING THE GIFT OF DONATION. MTF ALSO IMPLEMENTED PROCESS EFFICIENCIES THAT WILL CONTINUE TO UTILIZE THE GIFT OF DONATION AND ALLOWS OUR SURGEON COLLABORATORS TO ELEVATE THEIR CONTINUUM OF CARE. IN THE PLASTIC AND RECONSTRUCTIVE SURGERY DIVISION, MTF CONTINUED TO INNOVATE IN PLASTIC SURGERY, WHILE PROVIDING SURGEON EDUCATION AND TRAINING. CONTINUED FOCUS WAS PLACED ON PROCESSING EFFICIENCIES AND DONOR RECOVERY METHODS TO MAXIMIZE THE GIFT OF DONATION WITH THE HELP OF ORGAN PROCUREMENT ORGANIZATIONS. MTF CONTINUED TO BOLSTER ITS INTER-INDUSTRY PARTNERSHIPS, INCREASING THE AVAILABILITY OF DONATED HUMAN TISSUE, AND THE ABILITY TO BRING HUMAN TISSUE ALLOGRAFTS TO SURGEONS AND PATIENTS. MTF'S WOUND CARE DIVISION CONTINUED GROWING THROUGHOUT 2023, EXPANDING ITS PRESENCE IN THE WOUND HEALING SPACE. MTF GENERATED MORE CLINICAL EFFICACY DATA, AS WELL AS HEALTH CARE ECONOMIC DATA FOR EXPANDED REIMBURSEMENT IN WOUND CARE AND PLASTIC AND RECONSTRUCTIVE SURGERY PROCEDURES, FURTHER ILLUSTRATING THE SAFETY AND VALUE OF ITS TISSUE FORMS. OUR GOAL IS SIMPLE-DO WHAT'S RIGHT FOR PATIENTS, SURGEONS, TISSUE DONORS, AND THEIR FAMILIES THROUGH OUR GUIDING PRINCIPLES: WE TRANSFORM BY PROVIDING SAFE, HIGH-QUALITY GRAFTS FROM DONATED HUMAN TISSUES THAT ARE USED IN A GROWING ARRAY OF CLINICAL FIELDS. WE COLLABORATE BY FORGING RELATIONSHIPS WITH EXPERTS IN TISSUE AND ORGAN RECOVERY, AS WELL AS LEADING PHYSICIANS AND SCIENTISTS, TO ACCELERATE INNOVATION AND ENSURE THE BEST POSSIBLE EXPERIENCES AND OUTCOMES FOR PATIENTS. WE INNOVATE BY ADVANCING THE SCIENCE OF TRANSPLANTATION BY SUPPORTING RESEARCH WITHIN OUR OWN ORGANIZATION AND AMONG CLINICIANS AND RESEARCHERS WORLDWIDE. WE GIVE BACK BY REINVESTING IN RESEARCH TO POSITIVELY AFFECT LIVES ACROSS THE GLOBE. SINCE ITS INCEPTION IN 1987, MTF, THE NATION'S LEADING TISSUE BANK, HAS RECEIVED TISSUE DONATIONS FROM OVER 170,000 DONORS. IN 2023, MTF RECOVERED TISSUE FROM OVER 5,600 DONORS FOR USE IN MUSCULOSKELETAL AND BONE ALLOGRAFT APPLICATIONS, OVER 7,500 DONORS FOR USE IN GENERAL, AND PLASTIC SURGERY APPLICATIONS, OVER 800 BIRTH TISSUE DONORS FOR USE PREDOMINANTLY IN WOUND CARE APPLICATIONS AND OVER 800 DONORS FOR ORGANS AND TISSUES FOR RESEARCH. OVERALL, MTF DISTRIBUTED OVER 550,000 UNITS OF ALLOGRAFT TISSUE DURING 2023. MTF'S MISSION IS TO SAVE AND HEAL LIVES BY HONORING THE DONATED GIFT, SERVING PATIENTS AND ADVANCING SCIENCE. FOR INDIVIDUAL STORIES ABOUT DONOR FAMILIES, PLEASE VISIT MTF BIOLOGICS WEBSITE AT HTTPS://WWW.MTFBIOLOGICS.ORG/WHO-WE-SERVE/DONORS- COMMUNITY/DONORS-FAMILIES. STORIES ABOUT RECIPIENTS ARE ALSO AVAILABLE ON THE WEBSITE AT HTTPS://WWW.MTFBIOLOGICS.ORG/WHO-WE-SERVE/DONORS- COMMUNITY/RECIPIENTS.
    Geographies
    Not indicated
    Dates
    Jan 1, 2023 – Dec 31, 2023
    Source
    990
    No causes provided
    No populations provided
    –
    $461M